University of Pittsburgh logo

Kelly M. Bailey, MD, PhD

  • Assistant Professor of Pediatrics
  • Co-Director, Mario Lemieux Institute for Pediatric Cancer Research

Administrative Assistant: Carla Clarke

Dr. Kelly Bailey is a physician scientist in the Division of Pediatric Hematology and Oncology at the UPMC Children’s hospital of Pittsburgh and an Assistant Professor of Pediatrics at the University of Pittsburgh School of Medicine. Dr. Bailey is the Co-Director of the Mario Lemieux Institute for Pediatric Cancer Research at UPMC Children’s. Dr. Bailey received her MD and PhD (Cancer Cell Biology) from West Virginia University. She completed a pediatric residency integrated research program at The University of Michigan in 2013 followed by a fellowship in Pediatric Hematology and Oncology. 

Dr. Bailey is a pediatric oncologist specializing in the clinical treatment and biology of bone sarcomas, with a focus on the adolescent primary bone tumor Ewing sarcoma. She directs a laboratory-based research program that focuses on understanding the intersection of DNA damage and immunobiology with the translational goal of discovering better treatment options for patients with advanced Ewing sarcoma. Dr. Bailey was awarded the UPMC Children’s Resident Teaching award in both 2018 and 2022. Nationally, Dr. Bailey is a member of the Society for Pediatric Research. She holds leadership roles within the Children’s Oncology Group (COG), currently heading the Localized Ewing sarcoma Task Force, a group of 30+ national bone tumor experts tasked with developing the next national clinical trial for localized Ewing sarcoma. Dr. Bailey is also national Vice Chair for the COG clinical trial AOST2121, examining a maintenance immunotherapeutic for the treatment of relapsed osteosarcoma. 

Education & Training

  • BA, Chemistry, West Virginia University, 2001
  • MD, West Virginia University, 2010
  • PhD, Cancer Cell Biology, West Virginia University, 2010
  • Residency in Pediatrics, Integrated Research Program, University of Michigan, 2010-2013
  • Fellowship in Pediatric Hematology and Oncology, University of Michigan, 2013-2016

Selected Publications

 

Lopez-Nunez O, Cafferata B, Santi M, Ranganathan S, Pearce T, Kulich S, Bailey K, Broniscer A, Rossi S, Zin A, Nasrallah M, Li M, Zhong Y, Alaggio R, and Surrey L. The spectrum of rare central nervous system (CNS) tumors with EWSR1-non-ETS fusions: Experience from three pediatric institutions with review of the literature. Brain Pathol. 2021 Jan;31(1):70-83.

Maurer LM, Daley JD, Mukherjee E, Venier RE, Julian CM, Bailey NG, Jacobs MF, Kumar-Sinha C, Raphael H, Periyapatna N, Weiss K, Janeway KA, Mody R, Lucas PL, McAllister-Lucas LM, Bailey KM. BRCA1-associated RING domain-1 (BARD1) loss and GBP1 expression enhance sensitivity to DNA damage in Ewing sarcoma. Cancer Research Communications, (2022) 2 (4): 220–232.

Daley J, Williams N, Salgado CM, Schultz C, Meade J, Ozolek J, Lindsey B, Bailey KM. Cutaneous Ewing Sarcoma Presenting as a Second Primary Malignancy in a Child. Journal of Pediatric Hematology/Oncology. 2022 Apr 14. doi: 10.1097/MPH.0000000000002457. Online ahead of print. PMID: 35426856

Weiss KR, Bailey KM. A druggable rheostat for Ewing sarcoma? Clin Cancer Res. 2022 Aug 3:CCR-22-1794. doi: 10.1158/1078-0432.CCR-22-1794. Online ahead of print. PMID: 35921177

Venier RE, Grubs RE, Kessler E, Cooper KL, Bailey KM, Meade J. Evaluations of barriers to referral for cancer predisposition syndromes in pediatric oncology patients in the United States. J Genet Couns. 2022 Aug;31(4):901-911.

Shulman D, Whittle S, Surdez D, Bailey K, de Álava E, Yustein J, Shlien A, Hayashi M, Bishop A, Crompton B, DuBois S, Shukla N, Leavey P, Lessnick s, Kovar H, Delattre O, Grunewald T, Antonescu C, Roberts R, Toretsky J, Tirode F, Gorlick R, Janeway K, Reed D, Lawlor E, and Grohar P. An international working group consensus report for the prioritization of molecular biomarkers for Ewing sarcoma. NPJ Precision Oncology, 2022 Sept 17;6(1):65 PMID 36115869 .

Cillo AR, Mukherjee E, Bailey N, Onkar S, Daley J, Salgado C, Li X, Liu D, Ranganathan S, Burgess M, Sembrat J, Weiss K, Watters R, Bruno TC, Vignali DAA, and Bailey KM. Ewing sarcoma and osteosarcoma have distinct immune signatures and intercellular communication networks. Accepted, Clinical Cancer Research 2022 Sept 8, PMID 36074145.

Daley JD, Olson AC, Bailey KM. Harnessing immunomodulation during DNA damage in Ewing sarcoma. Front Oncol. 2022 Nov 22;12:1048705. doi: 10.3389/fonc.2022.1048705. PMID: 36483025

Daley J, Halligan K, Howrie D, Salgado CM, Superdock A, Friehling E, Bailey KM. Successful Treatment of Patient With Ewing Sarcoma in the Setting of Inherited Cholestatic Liver Disease. J Pediatr Hematol Oncol. 2023 Jan 12. doi: 10.1097/MPH.0000000000002623. Epub ahead of print. PMID: 36728269.

Gao Y, He X-Y, Wu HS, Huang Y-H, Toneyan S, Ha T, Ipsaro JJ, Koo JK, Joshua-Tor L, Bailey KM, Egeblad M, and Vakoc CR. ETV6 dependency in Ewing sarcoma by antagonism of EWS-FLI1-mediated enhancer activation. Nature Cell Biology 2023 Jan 19. PMID: 36658219.

Full Publication List via NIH PubMed »

Academic and Research Interests

  • Ewing sarcoma
  • Pediatric sarcomas
  • DNA damage
  • Immunobiology
  • HUmanized mice
  • Sarcoma therapies
  • Radiation therapy

Research Grants

 

2023-2024 Charlie Landers Foundation, Role of Galectin-3 in metastatic Ewing sarcoma. Specific Role, PI, 1 year.  

 2022-2024 Alex’s Lemonade Stand Foundation Innovator Award, Impact of STAG2 loss on Ewing sarcoma immunobiology, Specific Role: PI, 2 years

 2021-2026 NIH NCI K08: 1K08CA252178-01A1, DNA Damage and Immunogenicity in Ewing sarcoma, Specific Role: PI, 5 years